Identification of a novel spliced variant of the SYT gene expressed in normal tissues and in synovial sarcoma by Tamborini, E et al.
Synovial sarcoma (SS), which accounts for approximately 10% of
soft tissue sarcomas, mostly affects young adults (Enzinger and
Weiss 1995). It develops mainly in the juxta-articular regions in
close association with tendon sheaths, and occasionally in the
abdominal wall and head and neck regions (Fetsh and Meis 1993;
Miloro et al, 1994; Zeren et al, 1995), lung and pleura (Hisaoka 
et al, 1998; Nicholson et al, 1998) and several other sites (Cielette
et al, 1994; Nielsen et al, 1996; Fritsch et al, 2000). Histologically,
a biphasic variant, composed of varying proportions of epithelial
and spindle cells and a monophasic variant, containing exclusively
spindle cells, are recognized (Fisher, 1986). 
Cytogenetically, SS is characterized by the non-random translo-
cation t(X;18) (p11.2-q11.2) (Turc-Carel et al, 1987), which gener-
ates the fusion of 2 genes, SYT on chromosome 18 and SSX on
chromosome Xp11.2 (Clark et al, 1994), where 5 highly homolo-
gous genes (SSX1 to SSX5) have been so far described (Crew 
et al, 1995; De Leeuw et al, 1996). At present, 3 different types of
translocations have been identified in SS, involving SSX1, SSX2
(Crew et al, 1995; de Leeuw et al, 1995) and SSX4 (Skytting et al,
1999). A strong association between SYT-SSX fusion type and
morphology has been documented (Kawai et al, 1998; Nilsson 
et al, 1999; Antonescu et al, 2000), even if exceptions occur (Crew
et al, 1995; Kashima et al, 1997; Tsuji et al, 1998; Mancuso et al,
2000). 
The SYT gene is expressed in a variety of embryonic and adult
tissues (de Bruijn et al, 1996). The corresponding protein,
composed by 387 amino acids, is rich in glutamine (19%), proline
(16%) and glycine (14%). Comparison database studies have
shown the presence of 3 putative SH2 and one SH3 binding
domains and an annexin-like imperfect direct repeat (Clark et al,
1994; de Bruijn et al, 1996). Even if no recognizable DNA-
binding domain is detectable, it has been recently demonstrated
that SYT protein is able to transactivate transcription when
targeted to a reporter gene (Brett et al, 1997). This transcriptional
role is supported by immunofluorescence experiments using poly-
clonal antibodies raised against the SYT protein alone or fused
with one of the SSX genes, showing that these proteins display a
nuclear localization (Brett et al, 1997; Dos Santos et al, 1997). 
The expression pattern of the SSX gene group is more
restricted: SSX1 and SSX2 transcripts are abundant in human
adult testis, expressed at low levels in the thyroid, and not
detectable in other normal tissues (Crew et al, 1995; Gure et al,
1997). The encoded proteins of 188 amino acids share 76% iden-
tity and 83% similarity and display, like SYT protein, a nuclear
localization. Some tyrosine phosphorylation sites have also been
detected (Crew et al, 1995; De Leeuw et al, 1996). 
SSX proteins have no defined DNA-binding sequence, but contain
2 well-preserved areas displaying a repressor activity, one resem-
bling Krüppel-associated box and the other (named SSXRD) located
in the COOH-terminal region. SSX proteins, in fact, can act as tran-
scriptional repressors when fused to a reporter gene (Brett et al, 1997;
Lim et al, 1998). However, the Krüppel-associated box-related
domain is not retained following the fusion with SYT gene: in the
chimaeric proteins the 8 C terminal amino acids of SYT are replaced
by 78 residues of SSX genes. The aberrant SYT-SSX proteins could
affect cell function and lead to neoplasia perhaps as a result of trans-
activation of other target genes not normally transcribed. 
Here we demonstrate that SYT mRNA is present in 2 forms one
of which, heretofore undescribed, contains an in-frame insertion of
93 bp sharing a 100% homology with the corresponding mouse
SYT gene. Coexistence of N-SYT and I-SYT, both fused with SSX,
was detected in a series of 59 SSs and in a SS cell line. Our data
suggest a critical role of the new I-SYT form in SS pathogenesis. 
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Tumours and patients 
59 SSs were analysed by RT-PCR on frozen material. 31 showed
the non-random translocation SYT-SSX1, 16 the SYT-SSX2 and
one the SYT-SSX4; in the remaining 11 tumours no specific fusion
transcript has been yet detected and these are the subject of further
studies. Among the SYT-SSX1 tumours, 16/31 (51.6%) were
monophasic and 15/31 (48.4%) biphasic; in the SYT-SSX2 group
12/16 (75%) were monophasic and 4/16 (25%) biphasic. The
single SYT-SSX4 tumour was monophasic. There were 21
primary tumours, 15 local relapses and 23 metastases; in 2 cases
(patients n. 27 and 42) we analysed both the primary tumour and
the metastasis, and in 4 cases (patients n. 25, 28, 41 and 55) we
analysed relapses and/or metastases (Table 2). 
The human synovial sarcoma CME cell line was kindly
provided by Dr B Kazmierczak (Renwick et al, 1995); these cells
had the typical (X;18) translocation and showed the SYT-SSX2
fusion transcript. 
6 normal tissue samples (kidney, stomach, liver, lung, colon and
synovia) derived from different patients surgically treated in our
Institute were also analysed. 
RNA extraction and reverse-transcription reaction
(RT-PCR) 
Total RNA was extracted using the RNAzol method (GIBCO
BRL, Life Technology) from snap-frozen tissue samples stored at
–80˚C. One mg of RNA was reverse-transcribed to cDNA with
oligo(dT) and random examers primers, using Superscript II
reverse transcriptase (GIBCO BRL, Paisley, UK), according to the
manufacturer’s conditions. One ml of cDNA was used as template
for each PCR reaction, which was performed using AmpliTaq
(Perkin Elmer), according to the manufacturer’s conditions. All
the amplification products were stained with ethidium bromide
and analysed on 1.8% agarose gel. 
SYT-SSX PCR 
The detection of the putative SYT-SSX1 or SYT-SSX2 fusion




PCR conditions were: 94˚C for 3 minutes, 35 cycles of denatura-
tion at 94˚C for 30 s, annealing at 58˚C for 30 s and elongation at
72˚C for 30 s; 5 minutes of terminal elongation at 72˚C (Kawai 
et al, 1998). 
The detection of the fusion transcript SYT-SSX4 was performed








The annealing temperature was 58˚C for 1 min (Skytting et al,
1999). Patients n. 30 (A) and n. 13 (B) were chosen to amplify the
full-length cDNA of both SYT-SSX1 (patient A) and SYT-SSX2
(patient B), using GOLD AmpliTaq and the following primers: 
SYT FL F: 5¢-TGG ATG GGC AAC ATG TC-3¢
SSX1 FL R: 5¢-CTC ATC AAG GGC ATG TGT 
CGT AT-3¢
SSX2 FL R: 5¢-TGG GCA TGT GTC GTA TCC 
CTG AGG-3¢
PCR conditions were: 96˚C for 8 min, 35 cycles of denaturation
at 94˚C for 30 s, annealing at 50˚C for 30 s and elongation at 72˚C
for 2 m; 5 min of terminal elongation at 72˚C. 
Cloning into pGEM-T vector 
PCR products of full-length SYT-SSX1 and SYT-SSX2 were
cloned into pGEM-T vector (Promega), according to the manufac-
turer’s conditions. After ligation and transformation into compet-
ent E. coli DH5 alfa cells, recombinant clones were isolated by
PCR screening (using T7 and SP6 universal primers) and subse-
quently entirely sequenced. 
DNA sequencing 
All the sequence reactions were carried out using an automated
sequencing system (377 DNA Sequencer, ABI PRISM PE,
Applied Biosystem) following standard protocols. 
Internal PCR 
We used an upstream 5¢ primer to amplify the fusion transcript
(SYT-SSX1 or SYT-SSX2) including a bigger fragment of the 5¢
portion of SYT gene: 
SYT 500 F: 5¢-GCC ATC ATC ACA GAG CAT GC-3¢
SSX1: 5¢-GGT GCA GTT TCC CAT CG-3¢
SSX2: 5¢-GGC ACA GCT CTT TCC CAT CA-3¢
PCR conditions were: 94˚C for 3 min, 25–35 cycles of denatu-
ration at 94˚C for 30 s, annealing at 56˚C for 30 s and elongation at
72˚C for 1 min; 5 min of terminal elongation at 72˚C. 
Normal tissues SYT cDNA was amplified using GOLD
AmpliTaq and the following primers: 
SYT 500 F: 5¢-GCC ATC ATC ACA GAG CAT GC-3¢
SYT 1000 R: 5¢-CTG TCC TGG GTA ACC TTG CTG
CCC-3¢
PCR conditions were: 96˚C for 8 min, 25 to 35 cycles of 
denaturation at 94˚C for 30 s, annealing at 56˚C for 30 s and 
elongation at 72˚C for 1 min; 5 min of terminal elongation at 72˚C. 
SYT 500 F and SYT 1000 R primers corresponds to bp 515–535
and 981–1005 of SYT cDNA sequence (GenBank Accession n.
X79201). 
Densitometric analysis 
PCR reactions used for densitometric analysis were performed at
different total cycles (25, 30 and 35). Samples were run in a 1.8%
agarose gel and analysed by Image Master VDS Scan Program
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where a PCR saturation was detected, were avoided. Each lane
was analysed separately and the numeric value obtained by the
scanning of the electrophoretically higher band was divided by the
value of the lower one. The calculated ratio between the software
value of I-SYT and N-SYT for each PCR reaction is reported in
column R of Table 2 and was performed on only 39/59 tumours
and CME synovial sarcoma cell line cDNAs. 
RESULTS 
Detection of two forms of SYT gene 
By amplifying the full-length cDNA of transcripts SYT-SSX1 (Table 1,
case n. 13) and SYT-SSX2 (Table 1, case no. 30) two bands for each
amplification reaction were detected (Figure 1A). To avoid cross reac-
tivity during the sequencing procedures and to verify their specificity,
we cloned the 2 bands obtained from each patient into pGEM-T vector.
After PCR screening, we selected clones containing 2 different inserts
for each type of fusion transcript. The subsequent sequencing revealed
that the 2 lower bands of 1390 bp (one from SYT-SSX1 and one from
SYT-SSX2) had a 100% homology with the already described fusion
transcripts, while the higher ones showed a novel sequence, corre-
sponding to an in-frame insertion of 93 bp in position n. 896 of the SYT
gene (GenBank Accession AF244972). Comparative analysis of this 93
bp inserted sequence, responsible for the addition of 31 residues,
revealed a 100% homology with the mouse SYT gene (Figure 1B).
After amplification with the same primer pairs for the mouse SYT gene,
from mouse liver and lung cDNA (kindly provided by Dr Manenti), we
detected the same two bands observed in humans, as confirmed by
sequencing procedures (Figure 1C). 
Analysis of a series of human normal tissues 
In order to verify if these 2 SYT forms were also present in normal
tissues cDNAs, we performed a PCR amplifying the SYT gene
only, using SYT500F and SYT1000R as primer pairs (Figure 2A).
A control PCR was done on an housekeeping gene, beta actin (data
not shown). In all the analysed tissues (Figure 2B), 2 bands of 583
and 490 bp were detected. Their sequencing revealed that the
former correspond to the new SYT form (here named I-SYT),
while the latter corresponded to the already described SYT gene
(here named N-SYT). 
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Table 1 Densitometrical analysis on normal tissues 
Kidney Stomach Liver Lung Colon Synovia 
%I-SYT 25.9 11.2 14.5 14.1 11.8 15.9 
%N-SYT 74.1 88.8 85.5 85.9 88.2 84.1 
Total 100.0 100.0 100.0 100.0 100.0 100.0 
I-SYT/N-SYT 0.35 0.12 0.17 0.16 0.13 0.19 
MC
- 12
Figure 1 (A) RT-PCR of the full length cDNA of two synovial sarcomas. 
M = molecular weight marker. 1 = Case no. 13 of Table 2 (SYT-SSX1). 2 =
Case no. 30 of Table 2 (SYT-SSX2). C–= no DNA was added to the PCR
reaction. 
(B) Aminoacidic translation of I-SYT and N-SYT. 1090 E Tamborini et al
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Analysis of a series of 59 synovial sarcomas 
Following the detection of I-SYT and N-SYT forms in the normal
tissues, we explored the SYT gene status in the series of 59 SSs
already characterized for the presence of specific fusion transcripts.
We performed PCR using SYT500F coupled to SSX1 for SYT-
SSX1 fusion transcript, or SSX2 for SYT-SSX2, in order to selec-
tively amplify the rearranged SYT gene only. For SYT-SSX4 and
for tumour cases where no fusion transcript was detected, oligonu-
cleotide SYT1000R was used. All 59 SSs and the CME cell line
showed a coexpression of I-SYT and N-SYT (Figure 3), which we
designated as I-SYT-SSX and N-SYT-SSX, respectively. 
Partial determination of exon/intron structure of SYT
gene 
A BLAST comparison of the novel 93 bp insertion sequence
present in I-SYT form was made against HTGS data base of NCBI
GenBank, retrieving clone RP11-737G21, Accession Number
AC027229, which contains unordered genomic sequences of
human chromosome 18. 
This revealed that the 93 bp insertion was delimited by genomic
sequences not detected in the SYT cDNA. In turn, these sequences
were followed by the SYT cDNA portions present at the insertion
site (between bp 885 and 886 of SYT cDNA) (Figure 4). This led us
to postulate that the insertion represents another SYT exon,
preceded and followed by introns of 2631 bp and 701 bp, respect-
ively. This was confirmed by the finding of the canonic exon/intron
donor acceptor consensus sequences present at the ends of introns. 
Densitometrical analysis 
Analysis on normal tissue samples indicated a differential expression
between N-SYT and I-SYT, the former showing always a greater
intensity (Figure 2B). This was particularly true in the synovia,
where 84.1% N-SYT vs 15.9% I-SYT was detected (Table 1). 
In tumour cases a more heterogeneous expression pattern of 
I-SYT-SSX and N-SYT-SSX was observed, consistent with an
increase of the I-SYT-SSX/N-SYT-SSX ratio (Table 2, column R),
ranging from 0.34 to 13.7. 
No significant correlation was observed between the SYT type
and any type of these parameters: fusion transcript type, histolo-
gical subtype, grade, tumour size, and source of the specimens
(primary, relapse, metastasis) (data not shown). 
Figure 1 (C) Alignment of SYT cDNAs sequences. Sequence 1: mouse SYT cDNA derived from NCBI data base (Accession no. X93357). Sequence 2:
human I-SYT derived from normal synovia. Sequence 3: human N-SYT derived from normal synovia. Sequence 4: mouse N-SYT derived from a normal liverMolecular analysis of the SYT cDNA and of the fusion transcripts SYT-SSX1 and SYT-SSX2 1091
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Table 2 Summary of clinico-pathologic and molecular findings in 59 SSs. 
Case Histologic subtype Specimen type Fusion transcript SYT-SSX Densitrometical analysis 
%I-SYT-SSX Ratio 
%N-SYT-SSX (R) 
1M o M 1  
2 Mo R 1 42.1 0.73 
57.9 
3 Mo M 1 36 0.56 
64 
4 Bi M 1 51.9 1.08 
48.1 
5B i R 1  
6 Bi P 1 56.3 1.29 
43.7 
7M o P 1  
8 Bi P 1 49 0.96 
51 
9M o R 1  
10 Bi R 1 73 2.70 
27 
11 Bi P 1 40.8 0.69 
59.2 
12 Mo P 1 52.2 1.09 
47.8 
13 Bi M 1 77 3.35 
23 
14 Bi P 1 
15 Mo P 1 34.3 0.52 
65.7 
16 Mo R 1 79.8 3.95 
20.2 
17 Bi P 1 40.9 0.69 
59.1 
18 Bi M 1 70 2.33 
30 
19 Mo M 1 
20 Mo M 1 
21 Mo R 1 63.8 1.76 
36.2 
22 Mo M 1 
23 Bi P 1 58.6 1.42 
41.4 
24 Bi R 1 51 1.04 
49 
25a Bi R 1 43.1 0.76 
56.9 
25b Bi M 1 70.8 2.42 
29.2 
26 Bi M 1 49.7 0.99 
50.3 
27a Mo P 1 25.8 0.35 
74.2 
27b Mo M 1 43.5 0.77 
56.5 
28a Mo M 1 59.4 1.46 
40.6 
28b Mo M 1 61 1.56 
39 
29 Mo M 2 55.6 1.25 
44.4 
30 Moo P 2 75.8 3.13 
24.2 
31 Bi R 2 25.7 0.34 
74.3 
32 Mo R 2 52.5 1.10 
47.5 
33 Mo P 2 80.4 4.10 
19.6 
34 Bi P 2 79.2 3.81 
20.8 1092 E Tamborini et al
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DISCUSSION 
In this study 59 SSs (31 characterized by the non-random translo-
cation SYT-SSX1, 16 by SYT-SSX2, one by SYT-SSX4, and 11
without a specific fusion transcript) were analysed. Morpho-
logically, the series included 35 monophasic (16 with SYT-SSX1,
12 with SYT-SSX2, one with SYT-SSX4 and 6 without specific
transcript) and 24 biphasic (15 with SYT-SSX1, 4 with SYT-SSX2
and 5 without specific transcript) tumours. 
Following amplification of the whole cDNA from both SYT-
SSX1 and SYT-SSX2 we observed that a novel SYT form, here
designated I-SYT, was co-expressed with the usual normal SYT
form, here named N-SYT, both of them fused to SSX genes. The
novel SYT form showed an in-frame insertion of 93 bp which was
100% homologous with the mouse-corresponding sequence (de
Bruijn et al, 1996). Co-expression of I-SYT and N-SYT was
detected in all the analysed normal tissues (Figure 2B) according
with the already published data regarding the mouse gene expres-
sion (de Bruijn et al, 1996). 
Considering that this in-frame insertion was identical to the
mouse sequence and that both the I-SYT and the N-SYT forms
were present in normal tissues, we can conclude that SYT mRNA
can undergo 2 alternative splicing events. This assumption is rein-
forced by BLAST comparison with genomic chromosome 18
sequences detected in NCBI HTGS GenBank database, which
provided evidence that this 93 bp sequence is present in a genomic
human clone. Moreover, the extremities of the I-SYT insertion
sequence are clearly identifiable as exon donor and acceptor sites. 
We found that the alternative splicing mechanism was main-
tained after the translocation of the X chromosome. In fact, both
the I-SYT and the N-SYT forms were always detected after the
fusion with one of the SSX gene family members, albeit in
different amounts. More specifically, we observed that in normal
tissues the expression levels were about 85% for N-SYT and 15%
for I-SYT, suggesting a prevalent N-SYT expression, at least in
this group (Table 1). Why the alternative splicing mechanism is
driven toward N-SYT remains unknown. Most likely, the elevated
percentage of N-SYT messenger was the cause leading to the
isolation of only this human SYT sequence by Clark and co-
workers (Clark et al, 1994). 
By contrast, in tumour cases, the ratio (R) of I-SYT-SSX and N-
SYT-SSX showed a variable increase in SSs, where the I-SYT-
SSX expression level appeared enhanced over the all series.
This value was calculated specifically on the fusion transcript
35 Mo R 2 73 2.70 
27 
36 Mo P 2 57 1.32 
43 
37 Mo R 2 
38 Mo P 2 
39 Bi P 2 
40 Bi M 2 
41a Mo M 2 64.1 1.78 
35.9 
41b Mo M 2 74.3 2.89 
25.7 
42a Mo P 2 82 4.55 
18 
42b Mo M 2 85.5 5.90 
14.5 
43 Mo M 2 93.2 13.7 
6.8 
44 Mo P 2 33.9 0.51 
66.1 
45 Mo M 2 35.9 0.56 
64.1 
46 Mo P 2 68.2 2.14 
31.8 
47 Mo M 4 
48 Bi M 
49 Mo P 
50 Bi P 
47 Mo M 
51 Bi M 
52 Mo R 
53 Bi P 
54 Bi P 
55a Mo R 
55b Mo R 
56 Mo M 
57 CME - 1 35 0.54 
65 
P = primary tumour, R = relapse, M = metastasis, Mo = monophasic subtype, Bi = biphasic subtype. Ratio is calculated as
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messengers. In fact, in our PCR procedures we avoided the
analysis of the non-rearranged allele that may derive from normal
tissues and that may contaminate the tumour samples. 
When we compared the primary tumour and the metastasis in the
same patient, the R showed a constant increase in the metastatic
tissue with respect to the primary one, at least in one informative
case (Table 2, case n. 27) and this seemed to be maintained between
the relapse and the metastasis (case n. 25 of Table 2) as well as
between the subsequent metastases developed during tumour
progression (case n. 41 of Table 2). This trend of expression is
confirmed by real time PCR preliminary experiments that show an
increased level of I-SYT in the analysed cases. 
Biologically, the diversity in expression levels of the 2 SYT forms
in normal and tumoral tissues could be due either to a different
stability of the conformational structure of the chimaeric mRNA or to
a prevalent oncogenic activity of I-SYT form. The I-SYT protein, in
fact, contains 31 adjunctive residues (Figure 1B) with several
microdomains rich in Q, Y, P and G, that are always present in a
number of transcriptional co-activators (Tamkun et al, 1992; Strubin
et al, 1995) and which may modulate the activity of the I-SYT
protein. Functional studies are in progress to explore the in-vitro and
in-vivo tumorigenic properties of the newly isolated I-SYT form. 
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